MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dementia"

  • 2022 International Congress

    MoCA and MMSE subitems’ sensitivity across the PD-cognitive spectrum

    E. Fiorenzato, L. Zurlo, C. Cianci, M. Garon, T. Gandolfi, F. Pistonesi, L. Weis, A. Antonini, R. Biundo (Padua, Italy)

    Objective: To determine which Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE) subitems are more sensitive in detecting cognitive abnormalities in patients with PD…
  • 2022 International Congress

    Association between dihydropyridines and dementia conversion in Parkinson’s disease

    JH. Jung, SH. Jeong, SJ. Chung, HS. Yoo, K. Baik, BS. Ye, SJ. Kim, YH. Sohn, PH. Lee (Busan, Republic of Korea)

    Objective: To investigate the role of antihypertensive drugs, including dihydropyridines, on nigrostriatal dopamine and dementia conversion in Parkinson's disease Background: Several experimental and clinical studies…
  • 2022 International Congress

    Sex Differences for Tau Association with Cognition in Early Parkinson’s Disease

    E. Bayram, A. Tsai, K. Wang, I. Litvan (La Jolla, USA)

    Objective: To assess sex differences for cerebrospinal fluid (CSF) phosphorylated tau (p-tau) association with cognition in Parkinson’s disease (PD) Background: Tau biomarkers can predict cognitive…
  • 2022 International Congress

    Phenotypical and treatment response heterogeneity in a cohort of normal pressure hydrocephalus patients

    A. Di Maio, G. Lazzeri, F. Arienti, F. Ruggiero, F. Mameli, A. Di Fonzo, G. Franco (Milan, Italy)

    Objective: To clinically characterize a cohort of patients with normal pressure hydrocephalus (NPH) to identify possible clinical and humoral biomarkers that can predict the response…
  • 2022 International Congress

    Feasibility of in-person and remote delivery of Alexander technique course for care partners of people with neurodegenerative disease

    M. Gross, R. Cohen, J. Bellingham, P. Brisset, C. Condie, S. Lazaro, B. Mello, A. Abdelrahman, J. Becker, S. Smith, T. Moote, W. Trusty (Candler, USA)

    Objective: Test feasibility of in-person and remote delivery via Zoom of Alexander technique (AT) course to improve quality of life for care partners (CP) of…
  • 2022 International Congress

    Epileptic seizures in patients with parkinsonism: experience of a tertiary centre

    C. Azoia, R. Jesus, A. Costa, A. Velon, P. Guimarães (Vila Real, Portugal)

    Objective: We aim to evaluate seizure frequency in patients with parkinsonism in a tertiary centre. Background: Observational studies suggest that the prevalence of epilepsy in…
  • 2022 International Congress

    Long-term follow-up of subthalamic nucleus deep brain stimulation for Parkinson’s disease: survival and disability milestones

    R. Barbosa, L. Correia-Guedes, M. Cattoni, P. Pita-Lobo, A. Castro-Caldas, M. Fabbri, P. Bastos, H. Carvalho, L. Albuquerque, S. Reimão, A. Gonçalves Ferreira, J. Ferreirajos, M. Rosa, M. Coelho (Lisbon, Portugal)

    Objective: To characterize retrospectively the long-term survival of 109 PD patients after 8 years of STN-DBS and to identify the incidence of the milestones of…
  • 2022 International Congress

    Robust methods for missing covariates in longitudinal studies with application to biomarker research in Parkinson’s disease dementia

    L. Suttner, P. Zhang, S. Xie (Philadelphia, USA)

    Objective: We propose a nonparametric method for handling different types of missing covariates in longitudinal studies. We show that the proposed method outperforms multiple standard…
  • 2022 International Congress

    FACIAL EMOTION EXPRESSIVITY IN PARKINSON’S AND ALZHEIMER’S DISEASES

    A. Cannavacciuolo, A. Guerra, D. Colella, M. Salzillo, A. de Biase, G. Paparella, M. Canevelli, G. Bruno, A. Berardelli, M. Bologna (Pozzilli, Italy)

    Objective: We here aimed to comprehensively investigate facial emotion expressivity in Parkinson’s disease (PD) and Alzheimer’s disease (AD) patients compared to healthy controls (HCs). Background:…
  • MDS Virtual Congress 2021

    Therapy to Reduce dementia risk In Parkinson’s disease (TRIP): Proof-of-concept trial

    D. Pourzinal, A. Bakker, G. Byrne, K. Mcmahon, J. O'Sullivan, R. Adam, A. Lehn, D. Copland, J. Yang, G. Pontone, T. Au, R. Littleford, M. Chatfield, Z. Mari, N. Dissanayaka (Herston, Australia)

    Objective: The TRIP proof-of-concept study examines functioning of the hippocampal DG/CA3 subregion as a biomarker and therapeutic target for memory impairment in Parkinson’s Disease (PD).…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 36
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
    • Life expectancy with and without Parkinson’s disease in the general population
    • Effect of marijuana on Essential Tremor: A case report
    • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Covid vaccine induced parkinsonism and cognitive dysfunction
    • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
    • Patients with Essential Tremor Live Longer than their Relatives
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley